Emerging biotech boosts Worldwide Healthcare trust performance

NAV up 2.5%

Eve Maddock-Jones
clock • 2 min read

Japanese pharmaceutical and emerging biotechnology stocks were two key areas pushing the Worldwide Healthcare trust’s returns, according to its results.

The group published its unaudited six-month results up to 30 September today (23 November), revealing how healthcare stocks have acted more defensively amid macroeconomic volatility. The results showed the trust made 3.1% total return during the period, a turnaround from its 5.8% loss recorded in the previous half year report. This return was ahead of the MSCI World Healthcare Index benchmark's 2.1%. But according to the report, it was not a straightforward journey to outperformance. The company said the returns had not "been linear" as the first two months of the reporting period wer...

To continue reading this article...

Join Investment Week for free

  • Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
  • Get ahead of regulatory and technological changes affecting fund management
  • Important and breaking news stories selected by the editors delivered straight to your inbox each day
  • Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
  • Be the first to hear about our extensive events schedule and awards programmes

Join now


Already an Investment Week